Enabling More Targeted Interventions in Digital Immuno-oncology Therapy


We’re in a new era of cancer therapy innovation: 800 cell and gene therapy applications are currently under review with the FDA. In parallel, digital immuno-oncology (IO) solutions face growing demand. As oncologists have more options to offer their patients, they must keep up with clinical data to match each patient with the best therapy. BrightInsight is helping by enabling targeted, patient-specific interventions from clinically validated analysis of patient data.

A regulated digital health platform like ours empowers users to transfer, process, and analyze large and complex data sets, which enables algorithm development for oncologists to improve cancer diagnosis, treatment, and monitoring.

Gaining Insight from Patient Wearables

One such improvement is access to wearable sensors that can shorten in-patient hospital stays and allow patients to get home earlier. Wearables can track anything from heart rate to cancer symptoms, enabling quick intervention if the disease progresses. The algorithms offer predictions based on data from a patient’s wearable. Pairing the wearable with an app gives patients the ability to communicate with their care team without going in for an appointment, improving their sense of connection and reducing time and money spent commuting to Academic Medical Centers. For patients in rural areas, this makes a huge difference.

“Wearables can enable active communication between the patient and the care team, helping the patient feel connected,” says Chatrick Paul, Senior Vice President and Head of US Oncology Business at AstraZeneca. “That connection can make for a better patient experience, which in turn can improve outcomes.”

Managing the Deluge of New Data

As the IO field is flooded with new data from various sources, oncologists need better clinical decision support tools, especially better access to data at the right time to make informed decisions about their patients’ care. The industry is trending towards running tests and comparing the results with existing data sets rather than beginning new clinical trials. With this new perspective on leveraging data, Class III Software as a Medical Device can leverage existing data and allow care teams to select the right treatment for each patient without the delay of extensive trials.

Integrating and Aggregating Data

With biopharma companies, wearables, and health IT systems relying on siloed proprietary software that struggles to integrate with other systems, it’s hard to generate a holistic view of the current data. In fact, biopharma and diagnostic companies struggle to communicate effectively with each other. This makes the plethora of new data less value than it could be.

Joe Bernardo, Operating Partner at Linden Capital, points out, “Pharma and the diagnostic companies have completely different need sets and development timelines. Also, the commercialization of a diagnostic assay is very different from the commercialization of a drug in the IO space. We need to think about the average oncologist and get them activated.”

Even within a single company, there are many stakeholders in various locations who have different requirements and uses for the available data. How can we coordinate oncologists, primary care physicians, radiologists, clinicians who deliver chemotherapy, and social workers? The goal is to build an algorithm that will bridge their needs and ultimately benefit the patient. That can be done by appropriately leveraging rapidly incoming data.

Our Contribution

BrightInsight is on the cutting edge of this goal, providing a proven, compliant platform that captures, transmits, and analyzes data from medical devices, apps, software, and other products. You can learn more about how we’re enabling targeted interventions in our recent white paper, The Role of Digital Health in Immuno-oncology Therapy Development and Adoption.


Back to Blog